Drug intelligence / Profile preview

SHR-A1811 + camrelizumab

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A combination therapy consisting of SHR-A1811, a HER2-directed antibody-drug conjugate, and camrelizumab, a PD-1 inhibitor. SHR-A1811 is composed of trastuzumab (anti-HER2 antibody), a cleavable linker, and a topoisomerase I inhibitor payload. Camrelizumab is a humanized monoclonal antibody that blocks PD-1, preventing its binding to PD-L1 and consequently inhibiting immune escape of tumor cells.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on SHR-A1811 + camrelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-A1811 + camrelizumab.

Explore the full profile